Screener

Research And Development Expense

Name: Kura Oncology Research And Development Expense by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Kura Oncology·Products & Services·3 segments·Rolls up to R&D

Breakdown

Segment	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Ziftomenib	$29.95M	$37.58M	$40.32M	$34.73M	$36.88M
Darlifarnib	—	—	$8.49M	$6.84M	$6.57M
Discovery Stage Program	$2.09M	$1.49M	$1.74M	$1.91M	$1.4M
Total	$55.97M	$62.79M	$67.91M	$64.41M	$65.26M

Segments

ZiftomenibView metric

DarlifarnibView metric

Discovery Stage ProgramView metric